Icotrokinra: Physiology and What Research Reports

What icotrokinra is

Icotrokinra is a synthetic peptide investigated as an orally administered antagonist of the interleukin-23 receptor (IL-23R). Translational pharmacology work characterised it as a targeted oral peptide that selectively blocks the interleukin-23 receptor and inhibits signalling (PMID 40629250). A clinical pharmacology review described it as an oral interleukin-23 receptor antagonist peptide developed for the treatment of psoriasis (PMID 41817926).

The word peptide matters here for a structural reason. Most drugs that interrupt the IL-23 pathway are monoclonal antibodies given by injection. Icotrokinra belongs to a smaller class of engineered peptides designed to survive oral administration and reach a target normally addressed by large biologics, which is why the literature repeatedly labels it a "targeted oral peptide" (PMID 41191932).

Where the target sits in the body

Interleukin-23 is a cytokine released by activated antigen-presenting cells such as dendritic cells and macrophages. It acts on lymphocytes carrying the IL-23 receptor complex, sustaining type 17 immune responses that are implicated in plaque psoriasis. Two therapeutic strategies exist: neutralise the circulating cytokine, or occupy the receptor so the cytokine cannot deliver its message. Icotrokinra takes the second route, and researchers reported that it selectively blocks the receptor and inhibits downstream signalling (PMID 40629250).

Because IL-23R expression is concentrated on particular immune cell populations rather than distributed broadly, receptor-level blockade is often discussed as a way of narrowing the biological footprint of an intervention compared with agents acting on wider signalling hubs. A phase 3 programme placed icotrokinra directly alongside the oral small molecule deucravacitinib as an active comparator, which allowed those two oral mechanisms to be examined in the same randomised setting (PMID 40976249).

How icotrokinra is measured and studied

Pharmacokinetics

Translational pharmacokinetic work modelled how the peptide behaves across species and linked exposure to receptor blockade and signalling inhibition (PMID 40629250). Oral peptides raise questions that injectable biologics do not — gastrointestinal stability, absorption and food effects among them — and a clinical pharmacology review compiled those characteristics for icotrokinra (PMID 41817926).

Pharmacodynamics

Beyond blood levels, investigators looked for biological read-outs. A phase 2b analysis in patients with moderate-to-severe psoriasis reported that icotrokinra induced early and sustained pharmacodynamic responses (PMID 41424381). Pharmacodynamic endpoints of this kind typically involve skin or blood biomarkers that track pathway activity, and they help establish whether an oral peptide is engaging its target rather than merely appearing in plasma.

Clinical endpoints

Dermatology trials generally use validated scores for plaque severity and clear-skin status, plus patient-reported measures. One trial specifically examined psoriasis involving high-impact sites — regions such as the scalp, face or genitals that weigh heavily on quality of life (PMID 41191932).

What the trials reported

The phase 3 programme reported by researchers used a once-daily oral schedule and compared icotrokinra with both placebo and an active oral comparator in participants with moderate-to-severe plaque psoriasis (PMID 40976249). A subsequent report presented one-year outcomes from those same trials, framed around durability of response in adults (PMID 42397072). A separate trial extended evaluation to adolescents as well as adults (PMID 41191940), and commentary on that work appeared in the surgical and general medical literature (PMID 41497080).

Adverse Events: What Studies Report

Several independent research groups pooled the randomised evidence. A systematic review and meta-analysis examined the efficacy and safety of icotrokinra for plaque psoriasis (PMID 42308521), and a second pooled analysis of randomised controlled trials addressed the safety and efficacy of oral icotrokinra in moderate-to-severe plaque psoriasis (PMID 41869308). A third meta-analysis of randomised controlled trials evaluated the same oral IL-23 receptor antagonist peptide in that population (PMID 41774413).

Individual trial reports carry the primary adverse-event tabulations, including the placebo- and active-comparator-controlled phase 3 trials (PMID 40976249) and the one-year follow-up report (PMID 42397072). Readers wanting event-level detail — categories, rates and discontinuations — should read those source publications directly rather than rely on a summary, because this page does not reproduce numbers that its cited titles and abstracts do not carry. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision.

Regulatory status

A drug-profile article documented icotrokinra's first regulatory approval and summarised the development programme behind it (PMID 42243571). Approval status is jurisdiction-specific and changes over time; regulatory labelling, not secondary literature, is the authoritative source for indication, population and prescribing information in any given country.

Why it matters to people reading about peptides

Icotrokinra is frequently encountered as an example of an oral peptide therapeutic. Historically, peptides have been given by injection because digestion degrades them, so a peptide that reached phase 3 psoriasis trials on a once-daily oral schedule (PMID 40976249) is often cited in discussions of oral peptide delivery generally.

Two clarifications are worth holding on to. First, icotrokinra is a prescription pharmaceutical evaluated in regulated clinical trials — it is not a research-chemical-style compound, and it is not interchangeable with the metabolic or cosmetic peptides that dominate consumer conversation. Second, its evidence base is specific: the published trials addressed plaque psoriasis, including disease at high-impact sites (PMID 41191932) and disease in adolescents as well as adults (PMID 41191940). Findings in one immune-mediated condition do not automatically transfer to others.

Limits of the current literature

• Condition-specific evidence. The randomised data summarised in the pooled analyses concern plaque psoriasis (PMID 42308521).
• Follow-up length. The longest durability report identified here covered one year (PMID 42397072).
• Comparator scope. The active-comparator evidence involved one oral agent, deucravacitinib (PMID 40976249), not the full range of available psoriasis therapies.
• Mechanistic depth. Pharmacodynamic characterisation drew substantially on a phase 2b dataset (PMID 41424381).

References

• Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling (Dermatology and Therapy, 2025)
• Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis (JCI Insight, 2025)
• Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents (New England Journal of Medicine, 2025)
• Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2) (Lancet, 2025)
• Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites (NEJM Evidence, 2025)
• Oral icotrokinra for plaque psoriasis in adults and adolescents (Annals of Medicine and Surgery, 2026)
• Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From ICONIC-ADVANCE 1 & 2 (British Journal of Dermatology, 2026)
• Icotrokinra: An Oral Interleukin-23 Receptor Antagonist Peptide for the Treatment of Psoriasis (American Journal of Clinical Dermatology, 2026)
• Efficacy and Safety of Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-analysis (Clinical and Experimental Dermatology, 2026)
• Safety and efficacy of oral icotrokinra for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials (Frontiers in Immunology, 2026)
• A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials (Inflammopharmacology, 2026)
• Icotrokinra: First Approval (Drugs, 2026)